Jaguar Health explores strategic alternatives for crofelemer rare disease program

Jaguar Health, Inc.

Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.
Timing aligns with planned NDA filing for crofelemer in rare intestinal failure diseases (MVID, SBS-IF).
Proof-of-concept trial in MVID/SBS-IF showed up to 37% reduction in parenteral support.
Market research estimates global nutritional support for MVID at ~$1.1B in 2026, rising to ~$1.5B in 2033.
CEO Lisa Conte to present updates at Life Sciences Virtual Investor Forum on June 24, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.